Results 21 to 30 of about 33,038 (222)

Novel Strategies for Treating Castration-Resistant Prostate Cancer

Biomedicines, 2021
The development of castration resistance is an inevitable pathway for the vast majority of patients with advanced prostate cancer. Recently, there have been significant breakthroughs in the understanding and management options of castration-resistant ...
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh   +3 more
doaj   +1 more source

Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer

Scientific Reports, 2023
Prostate cancer is the most prevalent cancer in men worldwide and is promoted by the sex hormone androgen. Expression of androgen from the testis can be significantly reduced through castration.
Won Sik Shin, Seung Hyun Han, Kyung Won Jo, Yunje Cho, Kyong-Tai Kim   +4 more
doaj   +1 more source

Visceral Disease in Castration-resistant Prostate Cancer [PDF]

European Urology, 2014
Metastatic involvement of the viscera in men with advanced castration-resistant prostate cancer (CRPC) has been poorly characterised to date. In 359 CRPC patients treated between June 2003 and December 2011, the frequency of radiologically detected visceral metastases before death was 32%.
Pezaro C. J., Omlin A., Lorente D., Nava Rodrigues D., Ferraldeschi R., Bianchini D., Mukherji D., Riisnaes R., Altavilla A., Crespo M., Tunariu N., De Bono J. S., Attard G.   +12 more
openaire   +3 more sources

20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. [PDF]

PLoS ONE, 2014
Castration-resistant progression of prostate cancer after androgen deprivation therapies remains the most critical challenge in the clinical management of prostate cancer.
Bo Cao, Yanfeng Qi, Yan Yang, Xichun Liu, Duo Xu, Wei Guo, Yang Zhan, Zhenggang Xiong, Allen Zhang, Alun R Wang, Xueqi Fu, Haitao Zhang, Lijing Zhao, Jingkai Gu, Yan Dong   +14 more
doaj   +1 more source

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience

Медицинский совет, 2021
Prostate cancer is one of the most common neoplasms in men. It currently ranks second in Russian Federation amongst male population in overall number of cases after only lung cancer and third in cancer mortality.
T. V. Ustinova, L. V. Bolotina, A. A. Paichadze, A. A. Kachmazov, A. A. Fedenko, A. D. Kaprin   +5 more
doaj   +1 more source

Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells

Cell Reports, 2023
Summary: The emergence of castration-resistant prostate cancer remains an area of unmet clinical need. We recently identified a subpopulation of normal prostate progenitor cells, characterized by an intrinsic resistance to androgen deprivation and ...
Ivana Steiner, Teresita del N.J. Flores-Tellez, Renaud Mevel, Amin Ali, Pengbo Wang, Pieta Schofield, Caron Behan, Nicholas Forsythe, Garry Ashton, Catherine Taylor, Ian G. Mills, Pedro Oliveira, Simon S. McDade, Dietmar M. Zaiss, Ananya Choudhury, Georges Lacaud, Esther Baena   +16 more
doaj   +1 more source

Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. [PDF]

PLoS ONE, 2012
As prostate cancer progresses to castration-resistant disease, there is an increase in signal transduction activity. Most castration-resistant prostate tumors continue to express the androgen receptor (AR) as well as androgen-responsive genes, despite ...
Hilary Whitworth, Shriti Bhadel, Melissa Ivey, Mark Conaway, Andrea Spencer, Ronald Hernan, Heather Holemon, Daniel Gioeli   +7 more
doaj   +1 more source

Knowledge mapping of immunotherapy in castration-resistant prostate cancer: a bibliometric and visualized study (2003–2022)

Frontiers in Urology, 2023
ObjectiveTo utilize bibliometric analysis to examine the literature about immunotherapy for castration-resistant prostate cancer published within the past two decades.
Xianfu Cai, Xianfu Cai, Chenguang Ding, Yang Li, Jin Zheng, Wujun Xue   +5 more
doaj   +1 more source

Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer

Cell Reports, 2018
Summary: The exact identity of castrate-resistant (CR) cells and their relation to CR prostate cancer (CRPC) is unresolved. We use single-cell gene profiling to analyze the molecular heterogeneity in basal and luminal compartments.
João D. Barros-Silva, Douglas E. Linn, Ivana Steiner, Guoji Guo, Adnan Ali, Hubert Pakula, Garry Ashton, Isabel Peset, Michael Brown, Noel W. Clarke, Roderick T. Bronson, Guo-Cheng Yuan, Stuart H. Orkin, Zhe Li, Esther Baena   +14 more
doaj   +1 more source

Darolutamide For Castration-Resistant Prostate Cancer.

OncoTargets and therapy, 2019
The treatment landscape of advanced prostate cancer continues to evolve rapidly, with newer and more active drugs being used in earlier phases of the disease based on improved overall survival. After adoption of docetaxel for metastatic castration-sensitive disease, large trials with next-generation androgen receptor-signaling inhibitors (abiraterone ...
Bastos,Diogo A, Antonarakis,Emmanuel S
openaire   +3 more sources